New drug duo targets advanced lung cancer in groundbreaking chinese trial

NCT ID NCT05195632

Summary

This study is testing a combination of two drugs, encorafenib and binimetinib, for Chinese adults with a specific advanced form of lung cancer (BRAF V600E mutated NSCLC). The main goals are to see how well the drugs shrink tumors and to monitor their safety. The trial is for patients who have not received certain targeted treatments before.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Fujian Medical University Union Hospital

    Fuzhou, China

  • Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian)

    Fuzhou, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, China

  • Hainan General Hospital

    Haikou, China

  • Harbin Medical University Cancer Hospital

    Harbin, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, China

  • Linyi Cancer Hospital

    Linyi, China

  • Peking University First Hospital

    Beijing, China

  • Peking University Shenzhen Hospital

    Shenzhen, China

  • Shandong Cancer Hospital

    Jinan, China

  • Shanxi Provincial Cancer Hospital

    Taiyuan, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • The First Affiliated Hospital of Jinzhou Medical University

    Jinzhou, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • The First Hospital of China Medical University

    Shenyang, China

  • The First Hospital of Jilin University

    Changchun, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, China

  • The Northern Jiangsu People's Hospital

    Yangzhou, China

  • The Second Hospital of Dalian University

    Dalian, China

  • Tianjin Cancer Hospital Airport Hospital

    Tianjin, China

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • Union Hospital Tongji medical college Huazhong University of Science and Technology

    Wuhan, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Yantai Yuhuangding Hospital

    Yantai, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Zhejiang University School of Medicine, Sir Run Run Shaw Hospital

    Hangzhou, China

Conditions

Explore the condition pages connected to this study.